Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 72Breast Neoplasms 9Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Prostate Cancer Metastatic 3Metastatic Castration Resistant Prostate Cancer 3Bulbo-Spinal Atrophy, X-Linked 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Metastatic Hormone Sensitive Prostate Cancer 2Melanoma 2mCRPC 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Solid Tumours 1Small Cell Lung Carcinoma 1Seizures 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Pancreatic Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrent Endometrial Endometrioid Adenocarcinoma × enzalutamide × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡